Outcomes with 8 mg Aflibercept: Does Prior DME Treatment Matter?

Nitish Mehta, MD

Show Description +

Nitish Mehta, MD, summarizes 48-week data for patients with DME who were treated with 8 mg aflibercept (Eylea HD, Regeneron) based on their prior DME treatment status.

Posted: 5/20/2024

Keywords:

retina-meeting-recap

•

Diabetic macular edema, DME

•

Regeneron Pharmaceuticals

•

Eylea

•

aflibercept

Up Next

Name: Outcomes with 8 mg Aflibercept: Does Prior DME Treatment Matter?
Uploaded: 2024-05-20T20:53:18+00:00
Description: Nitish Mehta, MD, summarizes 48-week data for patients with DME who were treated with 8 mg aflibercept (Eylea HD, Regeneron) based on their prior DME treatment status.

Imaging AMD: Microperimetry and OCT

Giulia Corradetti, MD

SriniVas R. Sadda, MD, Steps in as ARVO President

Vas Sadda, MD

Gene Therapy for Wet AMD: Pharmacodynamic Changes

Ramanath Bhandari, MD

Faricimab in the Real World: 2 Years of Data

Aamir Aziz, MD

Addressing the AMD Epidemic

Emily Chew, MD

Managing Concurrent Wet AMD and GA

Ted Leng, MD

A Look at Three-Year Data for Pegcetacoplan

Ashkan Abbey, MD

The Latest Data on Photobiomodulation

Todd Schneiderman, MD

A Subretinal Implant for GA: Improving Vision

Mahi Muqit, MD

Optogenetics for RP: 12-Month Data

Allen Ho, MD

New Data on Oral DR Therapy

Daniel Su, MD

Back to All Videos

Outcomes with 8 mg Aflibercept: Does Prior DME Treatment Matter?

Nitish Mehta, MD

Nitish Mehta, MD, summarizes 48-week data for patients with DME who were treated with 8 mg aflibercept (Eylea HD, Regeneron) based on their prior DME treatment status.

Posted: 5/20/2024

Keywords:

retina-meeting-recap

•

Diabetic macular edema, DME

•

Regeneron Pharmaceuticals

•

Eylea

•

aflibercept

Please log in to leave a comment.

Meeting Coverage:

Association for Research in Vision & Ophthalmology

Outcomes with 8 mg Aflibercept: Does Prior DME Treatment Matter?

Up Next

Outcomes with 8 mg Aflibercept: Does Prior DME Treatment Matter?

More From ARVO: 2024 Coverage